News | October 18, 2012

Accuray CEO Resigns, Board Appoints Successor for Next Phase of Growth

October 18, 2012 — Accuray Inc. announced the resignation of Euan S. Thomson as president and CEO, and director of the board. Accuray's board has appointed Joshua H. Levine as his successor, effective immediately. Thomson is anticipated to continue in a consulting role with the company.

Thomson joined Accuray in March 2002 as CEO, was appointed president in September 2002 and served on the board of directors. During his tenure, Thomson expanded the radiosurgery market with the company's flagship product, the CyberKnife system. He took the company public in February 2007 and led the company through the transformational acquisition of TomoTherapy in 2011. The acquisition of TomoTherapy added the TomoTherapy system to the company's product portfolio, which expanded Accuray into the radiation therapy market.

"I want to thank the board, Accuray employees and customers for their support and encouragement over the last 10 years as we together changed the way people think about treating cancer patients," said Thomson. "It's been a fulfilling experience, but I feel that after being CEO for 10 years, a change in leadership is healthy for the organization. It's time for change, for both the company and me."

"Euan was instrumental in growing Accuray's installed base from approximately 5 to more than 642 systems, and growing the company from approximately 75 to over 1,100 employees," said Louis J. Lavigne Jr., chairperson of the board. "The board would like to thank Euan for his 10 years of service and leading the company through the acquisition of TomoTherapy. With the acquisition of TomoTherapy we are now ready for the next stage of growth. Capitalizing on the progress made by Euan, the board attracted Joshua Levine, who the board believes is an experienced, commercially oriented CEO with diverse global healthcare experience necessary to lead the company to the next level of success."

Levine previously was CEO of Mentor Corp. where he led the company through a strategic transformation and was instrumental in its sale to a franchise of Johnson & Johnson in January 2009, and more recently was CEO of Immucor Corp. until October 2011, when it was acquired by TPG Capital.

"I am honored and excited about the opportunity to lead this great organization through its next phase of growth. Accuray has a history of technical innovations in the radiation oncology field that have helped support the personalized clinical needs of cancer patients and the radiation oncologists who treat them. I look forward to working with all of Accuray's talented and dedicated employees to help build profitable growth producing value for all of the company's constituents – shareholders, customers and employees alike," said Levine.

For more information: www.accuray.com

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers. #ASTRO18 #ASTRO2018

A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers.

Feature | Proton Therapy | November 01, 2018 | Dave Fornell, Editor
A few of the big takeaways from the American Societ...